title: Government regulators must steward drug transparency.
abstract: The pharmaceutical industry has recently taken steps to make clinical trial data more accessible. But for there to be meaningful transparency, governments—not drug companies—should set the terms of disclosure.
authors.affiliation: Faculties of Medicine and Law, Dalhousie University, Halifax, Nova Scotia, Canada.
authors.forename: Matthew
authors.initials: M
authors.lastname: Herder
mesh_terms: D002986:Clinical Trials as Topic / Q000331:legislation & jurisprudence*; D030881:Disclosure / Q000592:standards*; D004345:Drug Industry / Q000331:legislation & jurisprudence*; D033161:Government Regulation; D006801:Humans; D011640:Public Policy; D012107:Research Design / Q000592:standards
references.citation: BMJ. 2013 Nov 12;347:f6754
references.pmid: 24222673
references.citation: BMJ. 2014 Feb 26;348:g1615
references.pmid: 24574476